Developing a vaccine to prevent drug-resistant tuberculosis infections
Immunotherapeutic approach for the prevention of secondary infection with drug-resistant TB
['FUNDING_R01'] · SEATTLE CHILDREN'S HOSPITAL · NIH-11115677
This study is looking at new vaccines to help prevent tuberculosis (TB) from coming back or spreading again, and it's testing these vaccines in mice and guinea pigs to find the best options for people with TB.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SEATTLE CHILDREN'S HOSPITAL (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11115677 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a vaccine that can prevent active tuberculosis (TB) disease, reduce relapse after treatment, and prevent reinfection. It involves testing various vaccine candidates in animal models, specifically mice and guinea pigs, to determine their effectiveness. The study aims to establish better methods for evaluating vaccine efficacy, which could lead to improved treatment options for TB patients. By comparing different vaccine formulations and their immune responses, the research seeks to identify the most promising candidates for further development.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for tuberculosis, particularly those with a history of drug-resistant infections or those undergoing treatment for TB.
Not a fit: Patients who are not at risk for tuberculosis or those who have already been effectively treated and are not experiencing relapse may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective vaccine that significantly reduces the incidence of drug-resistant tuberculosis.
How similar studies have performed: Previous research has shown promise in developing vaccines for tuberculosis, but this specific approach is innovative and aims to address gaps in current vaccine efficacy evaluation.
Where this research is happening
SEATTLE, UNITED STATES
- SEATTLE CHILDREN'S HOSPITAL — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COLER, RHEA N — SEATTLE CHILDREN'S HOSPITAL
- Study coordinator: COLER, RHEA N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.